Y
amanaka's pioneering work demonstrating the ability of fully differentiated cells to reprogram into embryonic stem cells with just four factors (c-Myc, Oct3/4, Sox2, and Klf4) ushered in a new era of regenerative biology. 1 Although it is currently thought that reprogramming of differentiated cells to a pluripotent state involves multiple stochastic epigenetic events, progenitors with some degree of uni-or multipotency can be reprogrammed more easily with fewer factors. 2 Mouse neural stem cells can be reprogrammed to a pluripotent state with the addition of only one factor, Oct4. 3 The endogenous expression of Sox2, Klf-4, and c-Myc, as well as other intermediate reprogramming genes, by endogenous neural stem cells perhaps enables Oct4 to drive these cells to a pluripotent state. Even in reprogramming with nuclear transfer technology, nuclei donated from less differentiated cells or progenitor cells induce a higher efficiency of reprogramming than nuclei from terminally differentiated cells, suggesting that the epigenetic landscape of a less differentiated cell is more amenable to reprogramming than that of a terminally differentiated cell. 4 However, endogenous expression of reprogramming genes in somatic cells is not sufficient for inducing reprogramming with fewer factors. For instance, fibroblasts express c-Myc as well as Klf-4 but still require exogenous introduction of these genes or addition of small molecules to enhance the reprogramming process. 2, 5 Successful reprogramming with exogenous introduction of factors depends on multiple variables, including the epigenetic landscape of the cell to be reprogrammed, expression levels, correct balance, and continuity of transgene expression, as well as appropriate temporal silencing of transgene expression. 2 
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In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Ho et al demonstrate that human umbilical vein endothelial cells (HUVECs) derived from the placenta can be reprogrammed to a pluripotent state with just two factors, Oct3/4 and Sox2. 6 The authors show that HUVECs exhibit a high level of expression of Klf-4 before reprogramming. Moreover, fetal cells are highly proliferative, and a highly proliferative state promotes efficient reprogramming. 7 Based on these advantages, the authors successfully derive induced pluripotent stem (iPS) cell colonies from HUVECs within 2 weeks following introduction of Sox2 and Oct3/4. HUVECderived iPS cells express pluripotency genes; form teratomas; and differentiate into cells expressing endodermal, mesodermal, and ectodermal markers. The efficiency of reprogramming is comparable to that observed with reprogramming using four factors. 6 Moreover, the genes introduced into HUVECs are nononcogenic, providing a potentially safer clinical application for HUVEC-derived iPS cells. The easy availability of placenta-derived HUVECs and the ability of these cells to undergo 2-factor reprogramming make the placenta an extremely attractive cell source for iPS cell generation. Fetal cells have far fewer accumulated mutations than adult cells (Table) , also making them a potentially safer choice than adult cells. The field of iPS cells in regenerative medicine is still in its infancy, but virus-free iPS cells have been manufactured, albeit at a lower reprogramming efficiency. 7 The discovery of Ho et al raises the possibility of "banking" placenta-derived HUVECs or HUVEC-derived iPS cells for potential therapeutic use at a later stage. This study also raises interesting questions about the plasticity or potency of endothelial cells. Do HUVECs possess a small population of less differentiated cells that ultimately gave rise to the iPS colonies observed by the authors? Or are HUVECs more potent than we have hitherto known them to be? The high expression of Klf-4 and the ability of these cells to undergo similar rates of reprogramming with 2 factors and with 4 factors seem to suggest that there might be plasticity or potency inherent to endothelial cells. It is tempting to speculate about the epigenetic landscape of the adult endothelial cell and how it compares to its fetal counterparts. Endothelial stemness may not be far away.
